|

Chemotherapy Combined with Immunotherapy and Targeted Therapy in Cholangiocarcinoma

RECRUITINGSponsored by Second Affiliated Hospital, School of Medicine, Zhejiang University
Actively Recruiting
SponsorSecond Affiliated Hospital, School of Medicine, Zhejiang University
Started2024-09-01
Est. completion2025-03-31
Eligibility
Age18 Years+
Healthy vol.Accepted
View on ClinicalTrials.gov →

NCT06718257

Summary

This study aims to validate the efficacy and safety of GP/GEMOX combined with PD-1/L1 inhibitors and TKI agents in patients with advanced cholangiocarcinoma through a multicenter, retrospective study to guide clinical practice.

Eligibility

Age: 18 Years+Healthy volunteers accepted
Inclusion Criteria:

* Histologically or radiologically confirmed intrahepatic cholangiocarcinoma
* Initially treated with GP/GEMOX or GP/GEMOX combined with PD-1/L1 and TKI inhibitors

Exclusion Criteria:

* Direct surgery after hospitalization
* Initial treatment combined with local therapies (radiotherapy, radiofrequency, particle implantation, TACE, etc.)
* Initial treatment involving other comprehensive therapeutic regimens

Conditions2

CancerCholangiocarcinoma

Browse More Trials

Cancer trials

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.